Skip to content

The efficacy and safety of remimazolam in colonoscopy patients: a prospective, randomized clinical trial

The efficacy and safety of propofol and different doses of remimazolam in colonoscopy patients: a prospective, randomized clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100054053
Enrollment
Unknown
Registered
2021-12-07
Start date
2022-07-08
Completion date
Unknown
Last updated
2022-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless Enteroscopy

Interventions

Low-Rem:0.15 mg / kg remimazolam and 0.04 mg / kg as required
High-Rem:0.2 mg / kg remimazolam and 0.04 mg / kg as required
Propofol:2 mg / kg propofol and 0.4 mg / kg as required

Sponsors

Shanghai East Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who plan to undergo colonoscopy for early cancer screening; 2. Patients aged 18-80 years, gender is not limited; 3. Body mass index (BMI) 18.5~30kg/m^2; 4. The American Society of Anesthesiologists (ASA) is graded I to III.

Exclusion criteria

Exclusion criteria: 1. Patients who refuse to participate in the trial; 2. Those with a history of severe heart, brain, lung, liver, kidney and metabolic diseases; 3. Those who have a history of abnormal surgical anesthesia recovery in the past; 4. ECG prompt: heart rate 180mmHg and (or) diastolic blood pressure > 110mmHg in patients with preoperative hypertension, or < 90/60mmHg in patients with hypotension; 7. Those with neuromuscular system diseases and mental diseases; 8. Anemia patients; 9. Suspected abuse of narcotic analgesics or sedatives; 10. Those who are predicted to have or have had difficult airway; 11. Those who do not cooperate and cannot communicate.

Design outcomes

Primary

MeasureTime frame
Blood Pressure;

Secondary

MeasureTime frame
Heart Rate;Induction time;Recovery time;

Countries

China

Contacts

Public ContactLiao Lijun

Shanghai East Hospital

liao@pan-support.com+86 13817428913

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026